Elsevier Congratulates Beth Karlan, MD, Editor-in-Chief of Gynecologic Oncology on Her Appointment to the National Cancer Advisory Board

London, December 17, 2012Elsevier, a world-leading provider of scientific, technical and medical information products and services, is pleased to congratulate Beth Karlan, MD, Editor-in-Chief of Gynecologic Oncology on being appointed by U.S. President Barack Obama to the National Cancer Advisory Board (NCAB), along with five other leaders in cancer research.

The National Cancer Advisory Board, formed in 1971, has several responsibilities including advising and assisting the proceedings of the National Cancer Institute (NCI), one of 27 Institutes that make up the National Institutes of Health (NIH). According to the NACB’s charter, the board’s duties are to “review applications for grants for research and training and recommend approval for applications for projects which show promise of making valuable contributions to human knowledge.” Allocating resources and pursuing the best avenues for research is a crucial task, as the NCI spends about $4.9 billion each year on cancer research.

Elsevier applauds Dr. Karlan’s important work and her dedication to serving the research community.

# # #

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence,and ClinicalKey—and publishes over 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

Media contacts
Elizabeth Perill
Elsevier
+1 212 633 3833
e.perill@elsevier.com